{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-21-009384","form_type":"8-K","ticker":"AGTX","cik":"0001603345","company_name":"Agentix Corp.","filed_at":"2021-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.274523+00:00","generated_at":"2026-06-27T23:20:15.956387+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Agentix and RTI announce worldwide exclusive license for NAFLD, NASH, T2D, obesity candidates","bullets":["License covers RTI small-molecule candidates for NAFLD, NASH, T2D, and obesity.","Agentix must complete Phase I trials by Jan 15, 2023; Phase II by Oct 2025; Phase III by Oct 2028.","Agentix plans to file IND with FDA in ~12 months; RTI to assist with IND-enabling toxicology and GMP manufacturing.","No financial terms disclosed; pre-clinical data show efficacy in animal models of metabolic diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-21-009384","json":"https://secwatch.observer/filing/0001477932-21-009384.json","markdown":"https://secwatch.observer/filing/0001477932-21-009384.md","text":"https://secwatch.observer/filing/0001477932-21-009384.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603345/000147793221009384/0001477932-21-009384-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603345/000147793221009384/agtx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T23:20:15.956387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}